全文获取类型
收费全文 | 490篇 |
免费 | 34篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 4篇 |
妇产科学 | 8篇 |
基础医学 | 75篇 |
临床医学 | 65篇 |
内科学 | 61篇 |
皮肤病学 | 9篇 |
神经病学 | 95篇 |
特种医学 | 45篇 |
外科学 | 62篇 |
综合类 | 3篇 |
预防医学 | 42篇 |
眼科学 | 4篇 |
药学 | 29篇 |
肿瘤学 | 20篇 |
出版年
2021年 | 7篇 |
2020年 | 16篇 |
2019年 | 5篇 |
2018年 | 6篇 |
2017年 | 8篇 |
2016年 | 14篇 |
2015年 | 15篇 |
2014年 | 20篇 |
2013年 | 20篇 |
2012年 | 18篇 |
2011年 | 33篇 |
2010年 | 22篇 |
2009年 | 9篇 |
2008年 | 28篇 |
2007年 | 15篇 |
2006年 | 20篇 |
2005年 | 9篇 |
2004年 | 14篇 |
2003年 | 12篇 |
2002年 | 22篇 |
2001年 | 23篇 |
2000年 | 10篇 |
1999年 | 20篇 |
1998年 | 8篇 |
1997年 | 6篇 |
1996年 | 3篇 |
1995年 | 4篇 |
1994年 | 3篇 |
1992年 | 6篇 |
1991年 | 14篇 |
1990年 | 7篇 |
1989年 | 9篇 |
1988年 | 7篇 |
1987年 | 9篇 |
1986年 | 9篇 |
1985年 | 5篇 |
1983年 | 2篇 |
1979年 | 6篇 |
1978年 | 2篇 |
1976年 | 6篇 |
1975年 | 3篇 |
1974年 | 6篇 |
1973年 | 2篇 |
1972年 | 3篇 |
1971年 | 9篇 |
1970年 | 3篇 |
1969年 | 3篇 |
1968年 | 2篇 |
1967年 | 3篇 |
1966年 | 5篇 |
排序方式: 共有525条查询结果,搜索用时 31 毫秒
91.
Tin Tin Htar Myint Harish Madhava Paul Balmer Dina Christopoulou Sepideh Attal Damianos Menegas Ralf Sprenger Eric Bonnet 《Advances in therapy》2013,30(2):127-151
Introduction
Streptococcus pneumoniae can cause invasive pneumococcal diseases (IPD), such as bacteremic pneumonia, bacteremia, meningitis, and sepsis, and non-IPDs, such as otitis media, nonbacteremic pneumonia, and upper respiratory tract infections. It was estimated in 2000 that, worldwide, S. pneumoniae was responsible for 826,000 deaths annually in children aged between 1 month and 5 years. A 7-valent pneumococcal conjugate vaccine (PCV7) was licensed in 2000 in the USA and in 2001 in Europe.Methods
A literature search was performed in PubMed to identify studies assessing the impact of routine childhood PCV7 vaccination on pneumococcal morbidity and mortality. Here, the impact on IPD is reported.Results
A total of 37 articles reporting impact data on IPD were included in this review: four from Australia, 17 from western Europe, and 16 from North America. In vaccine-eligible children in the postvaccination period, a reduction ranging from 39.9% in Spain to 99.1% in the USA in vaccine-type (VT) IPD incidence, compared with the prevaccination period, was reported in 18 studies. All but one of the 30 studies assessing the impact of PCV7 on all-type IPD reported a reduction ranging from 1.7% in Spain to 76.3% in Australia. In addition, the majority of studies reported reductions in VT and all-type IPD incidence in age groups that were not vaccine eligible.Conclusions
The results from this review illustrate that PCV7 has had a significant impact on IPD across all ages through its use in pediatric immunization programs. With the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) further reductions in the incidence of IPD due to the six additional serotypes included, as well as continued protection against IPD due to PCV7 serotypes may be expected. Robust surveillance systems are essential for the evaluation of the impact of PCV13 on all-type IPD and for monitoring the evolution of non-VT IPD. 相似文献92.
93.
94.
Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response
Seifert CL Wegner C Sprenger T Weber MS Brück W Hemmer B Sellner J 《Multiple sclerosis (Houndmills, Basingstoke, England)》2012,18(7):1045-1049
We report a case of multiple sclerosis-associated fulminant tumefactive demyelinating lesion (TDL) with the special feature of delayed humoral immune response. Plasma exchange (PE) yielded significant benefit in two consecutive steroid-unresponsive relapses, while signs of an intrathecal B-cell response were only present 2 years later at the second relapse. Remission was achieved and sustained thereafter with natalizumab. Our case indicates that PE might be a therapeutic option even when the B-cell response is not fully developed. This delay in the development of a humoral immune response may reflect the step-wise B-cell colonization of the CNS and represent an attractive therapeutic window of opportunity. 相似文献
95.
96.
97.
Transfer of allergen-specific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation 总被引:4,自引:0,他引:4
J M Agosti J D Sprenger L G Lum R P Witherspoon L D Fisher R Storb W R Henderson 《The New England journal of medicine》1988,319(25):1623-1628
We investigated whether allergen-specific IgE-mediated hypersensitivity is transferred by bone marrow transplantation. Twelve patients, 14 to 47 years of age, undergoing allogeneic bone marrow transplantation for the treatment of hematologic cancer were selected, along with their donors, by a screening questionnaire for a history of atopy in the donor. We evaluated these donor-recipient pairs before transplantation and at several points afterward for immediate skin-test reactivity to 17 allergens. For allergens for which pretransplantation skin tests had been positive in the donors and negative in the recipients, 20 of 46 post-transplantation skin tests were positive in 8 of the 11 recipients who survived for more than one year after transplantation. For allergens for which both donors and recipients had had negative skin tests before transplantation, only 6 of 256 tests (2.3 percent) were positive in the recipients after transplantation. Long-term transfer of donor-derived mite-specific IgE was demonstrated by radioallergosorbent testing in two recipients. Seven recipients either acquired or had an exacerbation of allergic rhinitis, and two recipients without a history of asthma had asthma one year after transplantation. We conclude that allergen-specific IgE-mediated hypersensitivity is adoptively transferred by bone marrow transplantation from donor to recipient by B cells with allergen-specific memory. 相似文献
98.
Bias and precision analysis of diffusional kurtosis imaging for different acquisition schemes 下载免费PDF全文
99.
Rationale
Zolpidem is a hypnotic drug that binds to γ-aminobutyric acid type A receptors but lacks consistently demonstrable anxiolytic efficacy. 相似文献100.
Aerts JM van Breemen MJ Bussink AP Ghauharali K Sprenger R Boot RG Groener JE Hollak CE Maas M Smit S Hoefsloot HC Smilde AK Vissers JP de Jong S Speijer D de Koster CG 《Acta paediatrica (Oslo, Norway : 1992). Supplement》2008,97(457):7-14
A biomarker is an analyte that indicates the presence of a biological process linked to the clinical manifestations and outcome of a particular disease. An ideal biomarker provides indirect but ongoing determinations of disease activity. In the case of lysosomal storage disorders (LSDs), metabolites or proteins specifically secreted by storage cells are good candidates for biomarkers. Potential clinical applications of biomarkers are found in improved diagnosis, monitoring of disease progression and assessment of therapeutic correction. These applications are illustrated by reviewing the use of plasma chitotriosidase in the clinical management of patients with Gaucher disease, the most common LSD. The ongoing debate on the value of biomarkers in patient management is addressed. Novel analytical methods have revolutionized the identification and measurement of biomarkers at the protein and metabolite level. Recent developments in biomarker discovery by proteomics are described and the future for biomarkers of LSDs is discussed. CONCLUSION: Besides direct applications for biomarkers in patient management, biomarker searches are likely to render new insights into pathophysiological mechanisms and metabolic adaptations, and may provide new targets for therapeutic intervention. 相似文献